FDA to Address Female Sexual Enhancement Drugs

LOS ANGELES — The topic of female sexual dysfunction — and drugs to treat it — will be front and center at an FDA meeting this month, one in a series of 20 looking at “patient-focused drug development.”

Critics have accused the Food and Drug Administration of having a gender bias, pointing out that it has approved six male-targeted drugs to help them overcome anxiety, physiology and more to get an erection, but has yet to approve a single female equivalent. 

The meeting to be held Oct. 27-28 will include statements from patients about the impact that female sexual dysfunction has had on their lives, WebMD reports. It will also include a scientific workshop to discuss how to diagnose the disorder and measure how well medications for it work.

Advocating for pharmaceutical gender inclusivity is Even the Score, a campaign that launched in June and is backed by the drug companies of at least three potential treatments for female sexual dysfunction.

A petition to the FDA posted by Even the Score on Change.org attracted more than 16,000 signatures. The petition addresses the FDA: “We urge you to work fairly and urgently toward a solution to an unmet medical need…”

Others, including the National Women’s Health Network and the American Medical Women’s Association, believe that the dearth of pharmaceutical options for women is not a gender bias, but a reflection of how much more complicated treating female sexual dysfunction can be.  

Following, they have supported the FDA’s decisions not to approve a drug for female sexual dysfunction, arguing that women may need more than a single pill to boost their libido. Viagra and Cialis target one important aspect of sex — the erection — but do not address psychological aspects of arousal, which may be key for women’s satisfaction,

Cindy Pearson, executive director of the National Women’s Health Network, says while the FDA has not been immune to gender bias, she doesn’t believe that is what’s delaying the drugs. “If it were gender bias, we would be yelling and screaming,” Pearson said. “The problem is the drugs. Our biology is so much more complicated than men’s.”

Related:  

Copyright © 2026 Adnet Media. All Rights Reserved. XBIZ is a trademark of Adnet Media.
Reproduction in whole or in part in any form or medium without express written permission is prohibited.

More News

'Group C' CEO Helena Catoir Meets With Pierre Woodman for 'Woodman Casting X' Game

Board game company Group C CEO Helena Catoir has met with casting director Pierre Woodman to discuss the new industry-themed release, “Woodman Casting X — The Game.”

Blush Debuts 'Candice' From 'EnLust' Stroker Collection

Blush has introduced the new Candice stroker sleeve from its EnLust line.

ProDx Health Joins SextPanther as New Testing Partner

ProDx Health has joined SextPanther as its new testing partner.

Honey Play Box Introduces 'Vibrosa Mini' Egg Vibe

Honey Play Box has debuted its new Vibrosa Mini app-controlled egg vibrator.

Blush Introduces 'Temptasia Ardor' Collection of Bondage Accessories

Blush has debuted its Temptasia Ardor collection of bondage accessories at the Altitude Intimates Show in Las Vegas.

SVibe Debuts 'Snail Twinn' Vibe

SVibe has introduced the new Snail Twinn clit-hugging vibrator.

Nalpac Releases 2026 Spring Lingerie Catalog

Nalpac has released its 76-page 2026 spring lingerie catalog, featuring hundreds of products.

Blush Introduces 'Queens Reign' Vibe Collection at Altitude Intimates

Blush has debuted its Queens Reign vibrator collection at the Altitude Intimates Show in Las Vegas, which runs until Tuesday.

Orion Debuts New Style From 'Cottelli Party' Line

Orion Wholesale has added a new style from its Cottelli Party line.

Eye of Love to Debut 'Kiss Chemistry' Collection From 'Matchmaker' Line at Altitude Intimates

Eye of Love will introduce the Kiss Chemistry lip gloss collection from its Matchmaker line at the Altitude Intimates Show in Las Vegas, which begins on Sunday.

Show More